Kailera Therapeutics (NASDAQ:KLRA) Rating Increased to Strong-Buy at Jefferies Financial Group

Jefferies Financial Group upgraded shares of Kailera Therapeutics (NASDAQ:KLRA) to a strong-buy rating in a report released on Tuesday morning,Zacks.com reports.

Other research analysts have also issued reports about the company. JPMorgan Chase & Co. began coverage on Kailera Therapeutics in a research note on Tuesday. They set an “overweight” rating and a $30.00 price objective for the company. William Blair started coverage on Kailera Therapeutics in a research note on Tuesday. They set an “outperform” rating for the company. TD Cowen started coverage on Kailera Therapeutics in a research note on Tuesday. They issued a “buy” rating and a $57.00 target price for the company. Leerink Partners started coverage on Kailera Therapeutics in a research note on Tuesday. They issued an “outperform” rating and a $36.00 target price for the company. Finally, Evercore started coverage on Kailera Therapeutics in a research note on Tuesday. They issued an “outperform” rating for the company. Two equities research analysts have rated the stock with a Strong Buy rating and four have assigned a Buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $42.75.

Kailera Therapeutics Stock Performance

Kailera Therapeutics stock opened at $22.30 on Tuesday. Kailera Therapeutics has a 52-week low of $20.86 and a 52-week high of $28.23.

Insider Activity

In other Kailera Therapeutics news, major shareholder Rtw Investments, Lp bought 500,000 shares of the stock in a transaction dated Monday, April 20th. The stock was bought at an average cost of $16.00 per share, for a total transaction of $8,000,000.00. Following the completion of the purchase, the insider owned 10,776,820 shares in the company, valued at $172,429,120. This represents a 4.87% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Andrew T. Kaplan bought 8,398,438 shares of the stock in a transaction dated Monday, April 20th. The stock was acquired at an average price of $16.00 per share, with a total value of $134,375,008.00. Following the completion of the purchase, the director owned 26,255,581 shares of the company’s stock, valued at $420,089,296. This represents a 47.03% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last ninety days, insiders acquired 10,460,938 shares of company stock worth $167,375,008.

About Kailera Therapeutics

We are an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care by advancing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. Obesity is a chronic, progressive and debilitating disease that impacts over 1 billion people globally and requires long-term comprehensive treatment. Since obesity is the driving factor for more than 200 comorbidities and represents a significant contributor to increased morbidity and mortality, our vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives.